Acute Porphyria Drug Database

Monograph

M05BC01 - Dibotermin Alfa
Not porphyrinogenic
NP

Rationale
Dibotermin alfa is not metabolized by CYP. The osteoinductive protein is exclusively locally active. In patients subjected to pre-drilling of the bone marrow canal prior to nailing, the frequency of possibly porphyrogenic infection is increased and may motivate attention. There are no other physiological effects of relevance to acute porphyria.
Chemical description
Osteoinductive protein
Therapeutic characteristics
Dibotermin alfa is indicated for spinal fusion operation L4-S1 and open tibia reposition and marrow nailing via pre-drilled canal. It is administered as an injection in connection with marrow nailing or nailing through a predrilled canal.
Hepatic exposure
Insignificant.
Metabolism and pharmacokinetics
Dibotemin alfa is not recovered in the systemic circulation. Preclinical data suggest that any dibotermin alfa escaping the implant to circulation would be rapidly degraded in the same manner as other endogenous proteins. It is not metabolized by cytochrome P450 enzymes.

References

# Citation details PMID
*Drug reference publications
1. Sweetman SC, editor. Martindale: The complete drug reference. Dibotermin alfa. Pharmaceutical Press 2009.
*Government bodies
2. European Public Assessment Report, InducOs (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu
*Summary of Product Characteristics
3. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). InducOs.

Similar drugs
Explore alternative drugs in similar therapeutic classes M05B / M05BC or go back.

Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
InductOs · InductOs 1,5 mg/ml poeder, oplosmiddel en matrix voor implantatiematrix
Belgium
InductOs · InductOs 1.5 mg/ml matrice implant. (pdr. + solv. + matrice) flac.
United Kingdom
InductOs · InductOs 12mg powder and solvent and matrix for implantation matrix · InductOs 4mg powder and solvent and matrix for implantation matrix
Denmark
InductOs
Norway
InductOs
Poland
InductOs
Luxembourg
INDUCTOS
Iceland
InductOs
Finland
Inductos
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙